Advertisement
Advertisement

VYGR

VYGR logo

Voyager Therapeutics, Inc. Common Stock

4.15
USD
Sponsored
0.00
0.00%
May 13, 15:58 UTC -4
Closed
exchange

Pre-Market

4.06

-0.09
-2.27%

Voyager Therapeutics, Inc. Common Stock Profile

About

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Info & Links

CEO

Alfred Sandrock

Headquarters

75 HAYDEN AVENUE
LEXINGTON, MA 02421, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.voyagertherapeutics.com

Auditor

Ernst & Young LLP

Share holders

10

Employees

141

Voyager Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

245.07M

Enterprise Value

201.75M

Enterprise Value/EBITDA(ttm)

-1.60

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

5.85

Price to Book(mrq)

1.12

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-296.53%

Profit Margin(ttm)

-377.18%

Return on Equity(ttm)

-51.35%

Return on Invested Capital(ttm)

-51.74%

Return on Assets(ttm)

-39.38%

Income Statement

Revenue(ttm)

36.49M

Revenue Per Share(ttm)

0.60

Gross Profit(ttm)

36.49M

EBITDA(ttm)3

-125.78M

Net Income Available to Common(ttm)

-116.64M

Diluted EPS(ttm)

-2.03

Share Statistics

Beta (5Y Monthly)

1.38

52-Week Change

26.52%

S&P 500 52-Week Change

26.33%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

60.42M

Dividend Yield

0.00%

Float4

55.79M

% Held by Insiders

6.39%

% Held by Institutions

48.03%

Balance Sheet

Total Cash(mrq)

141.48M

Total Cash Per Share(mrq)

2.34

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

7.64%

Quick Ratio(mrq)

7.64%

Book Value Per Share(mrq)

3.32

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.26

Free Cash Flow(ytd)

-135.06M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement